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Abstract
The glycosaminoglycan chondroitin sulfate is a critical component of proteoglycans on the cell surface and in the
extracellular matrix. As such, chondroitin sulfate side chains and the sulfation balance of chondroitin play important roles in
the control of signaling pathways, and have a functional importance in human disease. In contrast, very little is known
about the roles of chondroitin sulfate molecules and sulfation patterns during mammalian development and cell lineage
specification. Here, we report a novel biphasic role of chondroitin sulfate in the specification of the cardiac cell lineage
during embryonic stem cell differentiation through modulation of Wnt/beta-catenin signaling. Lineage marker analysis
demonstrates that enzymatic elimination of endogenous chondroitin sulfates leads to defects specifically in cardiac
differentiation. This is accompanied by a reduction in the number of beating cardiac foci. Mechanistically, we show that
endogenous chondroitin sulfate controls cardiac differentiation in a temporal biphasic manner through inhibition of the
Wnt/beta-catenin pathway, a known regulatory pathway for the cardiac lineage. Treatment with a specific exogenous
chondroitin sulfate, CS-E, could mimic these biphasic effects on cardiac differentiation and Wnt/beta-catenin signaling.
These results establish chondroitin sulfate and its sulfation balance as important regulators of cardiac cell lineage decisions
through control of the Wnt/beta-catenin pathway. Our work suggests that targeting the chondroitin biosynthesis and
sulfation machinery is a novel promising avenue in regenerative strategies after heart injury.
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Introduction
The glycosaminoglycan chondroitin sulfate (CS) consists of
linear chains of repeating disaccharide units covalently linked to
cell surface and secreted proteins to form chondroitin sulfate
proteoglycans [1,2], which have been shown to control multiple
aspects of cellular behavior and communication [2]. Differentially
sulfated CS forms include the mono-sulfated chondroitin-4-sulfate
(C4S) and chondroitin-6-sulfate (C6S) units, as well as the di-
sulfated units chondroitin sulfate-D (CS-D) and chondroitin
sulfate-E (CS-E) [2,3]. CS biosynthesis and its sulfation balance
is tightly controlled by growth factor signaling [2,4,5], and in turn
can control cellular signaling pathways [6,7,8,9,10]. Moreover,
chondroitin sulfates have been functionally linked to various
human diseases, including cancer, osteoarthritis, malaria, and
others [2,11,12,13,14,15,16]. In contrast, more knowledge is
required in regards to the importance of chondroitin sulfate
molecules and sulfation patterns during mammalian development
and cell lineage specification. Some of the better-known functions
of chondroitin sulfates are in neural [17,18] and skeletal [2]
development and disease. Chondroitin sulphate proteoglycans are
key modulators of spinal cord and brain plasticity [18], and are
important molecular targets in therapies for spinal cord injuries
[19]. Chondroitin-4-sulfation negatively regulates axonal guidance
and growth in mice [20], and the regulation of a neuronal
phosphoproteome by chondroitin sulfate proteoglycans has been
described [9]. Moreover, CS plays roles in the control of signaling
pathways essential for the proliferation, self-renewal, and cell
lineage commitment of neural stem/progenitor cells [21]. We
have previously described severe embryonic skeletal abnormalities
and perinatal lethality in mice carrying a loss-of-function mutation
in the Chondroitin-4-sulfotransferase-1 (C4st-1) gene [7], demonstrat-
ing the critical importance of a proper balance of chondroitin
sulfation in cartilage development. These conclusions were
supported by other studies, which also identified skeletal abnor-
malities in loss-of-function mutations of a number of CS
biosynthesis enzymes [22,23]. Moreover, missense mutations in
the human Carbohydrate sulfotransferase 3 (CHST3) gene, involved in
the production of CS, have been shown to be associated with
Larsen syndrome, humero-spinal dysostosis [24], and Omani-type
spondyloepiphyseal dysplasia [25], all of which cause severe
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skeletal abnormalities. Taken together, the literature clearly
identifies a critical role for CS in mammalian neuronal and
skeletal development and disease. Recently, mild cardiac abnor-
malities, including mitral, tricuspid and aortic regurgitations, have
been described in a subset of Omani-type spondyloepiphyseal
dysplasia patients, but not in patients with Larsen syndrome or
humero-spinal dysostosis [26]. In contrast, CHST3 knock-out mice
and have neither skeletal nor cardiac defects [27]. Distinct
expression domains for CS and CS biosynthesis enzymes have
been described in the developing and mature mammalian heart
[4,28,29]; however, the functional roles of CS in heart develop-
ment or cardiac lineage development are not understood.
The Wnt/beta-catenin signaling pathway plays critical roles in
many developmental processes, and aberrant Wnt/beta-catenin
pathway activity is causally associated with many human diseases,
including cancers [30,31,32,33,34,35,36,37]. Wnt/beta-catenin
signaling also controls stem cell behavior, for example in the
intestinal epithelium [37,38,39,40,41,42] Wnt/beta-catenin sig-
naling also plays critical roles in embryonic stem (ES) cell renewal
and lineage determination [43]. In cardiac lineage development,
Wnt/beta-catenin has been shown to play a biphasic role
[44,45,46]. At early stages, pathway activity is required for
mesoderm formation, induction of precardiac mesoderm, and for
the expansion of cardiac progenitor cell. At later stages, Wnt/beta-
catenin signaling appears to inhibit the differentiation of cardiac
progenitor cells into functional cardiomyocytes [44,45,46].
Interestingly, CS has recently been shown to control the Wnt/
beta-catenin pathway. CS-E, but not other CS forms, can bind
Wnt3a ligand with high affinity [47]. We recently demonstrated in
NIH3T3 cells that treatment with CS-E could reduce activation of
Wnt3a-receptor complexes on the cell surface, and limits Wnt/
beta-catenin signaling to a threshold level of approximately 25%
[8]. This threshold differentially affected transcriptional and
biological readouts of Wnt/beta-catenin pathway activation [8].
Several studies have demonstrated a correlation of Wnt/beta-
catenin signaling levels with embryonic stem cell differentiation,
anterior specification during mouse embryogenesis, adult hepatic
homeostasis, phenotypic severity of intestinal tumorigenesis, and
lineage determination during hematopoiesis
[30,31,32,33,34,35,36,37,42,43]. Together, these results might
suggest that CS and the balance of chondroitin sulfation could
play a role in establishing critical Wnt/beta-catenin signaling
thresholds in development and disease.
Here, we initially set out to investigate the roles of CS in ES cell
differentiation in embryoid body (EB) cultures. We demonstrate by
lineage marker analysis that enzymatic elimination of endogenous
chondroitin sulfate by the bacterial enzyme Chondroitinase ABC
(ChABC) leads to a defect in cardiac differentiation, and causes a
reduction in the number of functional cardiac foci. We further
show that elimination of CS in EB cultures activates the Wnt/
beta-catenin pathway, a known regulatory pathway with a
biphasic function in cardiac lineage determination. Limiting
ChABC treatment to only early or late stages of ES cell
differentiation mimics the biphasic effects of Wnt/beta-catenin
pathway activation on cardiac differentiation. Temporally restrict-
ed treatment with a specific exogenous chondroitin sulfate, CS-E,
inhibits Wnt/beta-catenin signaling and phenocopies the biphasic
effects of endogenous CS on cardiac differentiation and Wnt/beta-
catenin signaling. Together, these results establish a novel biphasic
role of chondroitin sulfate in the specification of the cardiac cell
lineage during embryonic stem cell differentiation through
inhibition of the Wnt/beta-catenin pathway.
Materials and Methods
Reagents
Chondroitinase ABC (protease-free) and CS-E were obtained
from The Associates Of Cape Cod, USA. C4S was obtained from
Sigma Inc., USA.
ES Cell and Embryoid Body (EB) Culture
R1 ES cells and EBs were cultured as previously described [4].
Briefly, R1 ES cells were cultured on gelatinized tissue culture
plates in ES media containing Leukemia Inhibitory factor (LIF;
Gibco, USA). In experiments requiring LIF withdrawal, ES cells
were cultures for 6 days in the absence of LIF. For EB culture, ES
cells were trypsinized and plated on 24-well low cluster plates
(Costar, USA) in ES media without LIF. After 4 days, EBs were
transferred to gelatinized 12-well or 24-well tissue culture plates
for flat culture for an additional 8 days. Bi-daily treatments of EBs
included ChABC (10 mU/ml), CS-E (100 microgram/ml), or C4S
(100 microgram/ml), as previously described [8,48].
Immunofluorescence Microscopy
Immunofluorescence microscopy was performed as previously
described [8]. Briefly, ES cells were grown on gelatinized glass
slides (Biotek, USA). Following fixation in 4% PFA/PBS for 5
minutes and permeabilization in 0.1% Triton X100 for 2 minutes,
cells were blocked in 10% FBS/PBS, followed by over night
incubation with primary antibodies mouse anti-C4S or rabbit anti-
b-catenin (Santa Cruz Biochemicals, USA). This was followed by a
one-hour incubation with donkey anti-mouse or anti-rabbit Alexa-
Fluor-488 secondary antibody (Invitrogen, USA). DAPI was used
to counterstain nuclei, followed by mounting in Prolong Gold
Antifade (Invitrogen, USA). For proliferation assays, the Click-iT
EdU cell proliferation assay (Life Technologies, USA) was used.
mRNA Preparation and Quantitative Real Time PCR
(qPCR)
RNA was prepared using TRI Reagent or TRIZOL according
to the manufacturer’s instruction. Subsequently, 1.5 microgram of
RNA were reversed transcribed using MuMLV-Reverse Tran-
scriptase (Promega, USA), followed by real time amplification
using a 2xSYBR Green PCR Master Mix (Applied Biosystems,
USA, Fisher Scientific, USA, or Biotium, USA) on an Applied
Biosystems 7500 Real Time PCR platform in 15 microliter
reactions using an annealing temperature of 60uC.
The following primer pairs were used (59 to 39):
HPRT:
ATGCCGACCCGCAGTCCCAGC and CGAG-
CAAGTCTTTCAGTCCTGTCC
Oct4:
TTGGGCTAGAGAAGGATGTGGTT and GGAAAAGG-
GACTGAGTAGAGTGTGG
Nanog:
GTGCTGAGCCCTTCTGAATC and GAACTCTCCTC-
CATTCTGAAC
Brachyury:
CTGGCCACACCAGCATGCTGCC and GTAC-
CATTGCTCACAGACCAGAGACTG
Mesogenin:
CCGGGATCCTGGGTGAGACCTTCCTCAGC and
TGCCAAGCTTGGCCTGGGCTCTCTCCCGC
Fgf5:
GATTGTAGGAATACGAGGAGTTTTCAGCAAC and
TCTTGGAATCTCTCCCTGAACTTACAGTCA
Afp:
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AGCAAAAGCCTGAACTGACAGAGGAGCAG and
GTTTTGGAAATCAACTTTGGACCCTCTTCTGTG
Gata4:
AAGAGATGCGCCCCATCAAGACA and TGGGGA-
CAGCTTCAGAGCAGACAG
Nkx2.5:
GGCGTCGGGGACTTGAACACC and CGCACTCACTT-
TAATGGGAAG
Mlc-2v:
TGGGTAATGATGTGGACCAA and GGGAGGTTCTC-
CAAAGAGGA.
Conditioned Media
Wnt3a and control conditioned media were prepared from
commercially available L cells stably transfected with a Wnt3a
expression plasmid, or non-transfected control L cells (ATCC,
USA), as previously described [8].
Protein Isolation and Western Blot Analysis
Protein lysates from EBs were isolated in RIPA lysis buffer as
previously described [8]. Protein lysates were separated on 8–10%
SDS-PAGE gels as previously described (). Antibodies used
included rabbit anti-pSmad1, rabbit anti-Smad1/5, rabbit anti-
pSmad2, rabbit anti-Smad2/3, rabbit anti-pErk, rabbit anti-Erk,
rabbit anti-p-p38, rabbit anti-p38, rabbit anti-Lrp6, rabbit anti-
pLrp6 (all Cell Signaling Technology, USA), mouse anti-beta-
catenin (Santa Cruz Biotechnology, USA), cardiac myosin heavy
chain (Abcam, USA), anti-CS-E antibody GD3G7 [54,55,56], and
mouse anti-alpha-tubulin (Santa Cruz Biotechnology, USA).
TOPFLASH Reporter Assays
ES cells or EBs were transiently transfected with firefly
TOPFLASH [49] and Renilla luciferase transfection control
reporter constructs, using linear PEI (MW: 25,000; Polysciences,
USA; PEI/DNA ratio of 8:1) as a transfection reagent as
previously described [8]. Three hours post-transfection the cells
were stimulated with Wnt3a-CM or control L-CM for 24 hours.
Figure 1. CS expression in differentiating ES cells and EB cultures. (A) Schematic of EB culture protocol. (B) Morphology of cultured cells: ES
cells in the presence of LIF (d0); EBs in low cluster plates at day 4 (d4); EBs on tissue culture plates (d6; arrows point to forefront of cells migrating out
of initial spheric EB), EBs at day 12 (d12). Scale bar = 200 micrometer. (C) Expression of CS in ES cells and EBs. No staining for CS stubs (green) was
observed in the absence of ChABC treatment (top row). Bottom row: ChABC treatment of ES cells cultured in the presence of LIF also showed no CS
expression. Differentiation of ES cells through withdrawal of LIF for 6 days led to CS expression. EBs at d6 of differentiation showed moderate CS
expression, EBs at d12 of differentiation showed strong CS expression. Scale bar = 50 micrometer.
doi:10.1371/journal.pone.0092381.g001
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Dual luciferase assays were performed according to manufactur-
er’s instructions (Promega, USA; Biotium, USA).
Statistical Analysis
Experiments were performed in triplicates; appropriate statis-
tical analysis was conducted for comparisons among groups
(Student’s t-test).
Results
CS Expression During ES Cell Differentiation and EB
Culture
In order to investigate the roles of endogenous chondroitin
sulfates in ES cell differentiation, we employed a previously
established EB flat culture system [4]. R1 ES cells were cultured
on low cluster plates for 4 days, and then transferred to tissue
culture plates for another 8 days (Figure 1A). While undifferen-
tiated ES cells grow in clumps with well-defined borders (d0;
Figure 1B), withdrawal of LIF and differentiation in low cluster
plates leads to large round unattached EB structures (d4;
Figure 1B). Transfer to tissue culture plates leads to attachment
and flattening of EB structures, with cells migrating out of the
central stucture at d6 (Figure 1B), and EBs covering most or all of
the well surface at d12 (Figure 1B). We then wanted to determine
whether CS moieties are expressed in ES cells or EB cultures. For
this, cultures were treated with the bacterial enzyme Chondroi-
tinase ABC (ChABC) at 10 mU/ml, previously demonstrated to
efficiently to eliminate chondroitin sulfate side chains of chon-
droitin sulfate proteoglycans (CSPGs) [48]. Subsequently, CS
expression was visualized by immunofluorescence microscopy
utilizing an antibody that recognizes the remaining CS stubs on
CSPGs after ChABC digestion (Figure 1C), as described
previously [12,48]. As a control, cells were not treated with
ChABC; indeed, no immunofluorescence signal was detected in
ES cells cultured in the presence or absence of LIF, or in EBs at d6
or d12 of differentiation (Figure 1C). When treated with ChABC,
undifferentiated ES (+LIF) cells showed no immunofluorescence
signal, while differentiation by withdrawal of LIF for 6 days lead to
expression of CS. Moreover, EB cultures at d6 and d12 showed
increasing levels of CS (Figure 1C). These data suggested that CS
Figure 2. Enzymatic elimination of CS accelerates loss of Nanog expression in differentiating ES cells. (A–D) Morphology of ES cell
cultures in the presence (A, C) or absence (B, D) of LIF, and in the presence (A,B) or absence (C,D) of ChABC. No major morphological changes were
observed in ChABC-treated cultures. Scale bar = 20 micrometer. (E) Quantitation of expression of the pluripotency markers Nanog and Oct4 by qPCR.
In the presence of LIF, treatment of ES cells with ChABC did not alter expression of Nanog and Oct4. In the absence of LIF, expression of Nanog and
Oct4 was downregulated in differentiating ES cells, as expected. Treatment with ChABC lead to a further reduction in Nanog expression levels. (F)
Western blot analysis of Nanog and Oct4 protein expression in the presence and absence of LIF and/or ChABC. Alpha-tubulin is shown as loading
control. (G) Quantitation of three independent Western blots: ChABC did not affect protein levels in ES cell cultures in the presence of LIF. Withdrawal
of LIF caused a reduction of Nanog and Oct4 protein levels, and concomitant treatment with ChABC caused an additional significant reduction in
Nanog protein levels, while not significantly affecting Oct4 levels (*p,0.05).
doi:10.1371/journal.pone.0092381.g002
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Figure 3. Lineage marker analysis in EB cultures reveals a role for endogenous CS in cardiac lineage development. (A) Morphology of
EB cultures on d4 and d12 of differentiation, in the presence or absence of ChABC treatment. No morphological differences were observed with
ChABC treatment. (B) Lineage marker analysis of EB cultures by qPCR. The pluripotency markers Oct4 and Nanog severely decreased during
differentiation, as expected. Treatment with ChABC did not affect the loss of Oct4 and Nanog, apart from a temporary reduction of Oct4 on d3.
Expression of the early ectoderm marker Fgf5 spiked on day 3 in control cultures, and then decreased drastically in later time points. Treatment with
ChABC showed the same pattern, with somewhat reduced expression on day 3 when compared to controls. Expression of the endoderm marker Afp
Chondroitin Sulfate in ES Cell Differentiation
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was initiated only after day 6, and rose steadily thereafter in control cultures. The same pattern was present with ChABC treatment; however, Afp
expression was reduced by 20% on d12. Expression of the early and axial mesoderm marker Brachyury spiked on d6, and was indistinguishable
between control and ChABC-treated cultures. Mesogenin as a marker of paraxial mesoderm also spikes at d6, but expression did not decline as fast as
expression of Brachyury. Treatment with ChABC led to an increased expression of Mesogenin on d9, but was equivalent to controls on d12.
Expression of the cardiac transcription factors Gata4 and Nkx2.5 started between d3 and d6 and peaked on d9, followed by a reduction on d12.
Treatment with ChABC led to an approximately 50% reduction in Gata4 and Nkx2.5 expression on d12. Expression of structural cardiac marker Mlc-2v
started only after d6, and increased dramatically by d12. EB cultures treated with ChABC displayed a severe reduction of Mlc-2v expression on d12
when compared to controls. (*p,0.05). (C,D) Western blot analysis of cardiac myosin heavy chain (MHC). MHC protein levels were significantly
reduced by treatment of EBs with ChABC (p,0.05).
doi:10.1371/journal.pone.0092381.g003
Figure 4. ChABC treatment reduces cardiac foci formation in EB cultures. (A) Ratios of beating cardiac foci corrected for total EBs plated in 8
independent experiments, and average ratio. Elimination of endogenous CS by ChABC led to a consistent, approximately 60% reduction in the
number of beating cardiac foci. (*: p,0.05). (B) Time course of cardiac foci development in EB cultures. In 4 independent experiments, ChABC
treatment lead to decreased numbers of cardiac foci even at d8 and d9, the earliest time points beating foci could be detected.
doi:10.1371/journal.pone.0092381.g004
Chondroitin Sulfate in ES Cell Differentiation
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side chains are not present at significant levels in undifferentiated
ES cells, but become upregulated during differentiation.
Elimination of CS in Differentiating ES Cells Affects
Pluripotency Markers
We next analyzed the effect of ChABC treatment on ES cell
morphology and expression of stem cell markers (Figure 2). While
ES cells cultured in LIF formed round structures with even borders
(Figure 2A), withdrawal of LIF for 6 days led to differentiation and
altered morphology of ES cell cultures, with a more flattened
appearance and uneven boundaries (Figure 2B), as previously
described [4,50]. Treatment with ChABC did not alter the overall
appearance of ES cells either in the presence (Figure C) or absence
(Figure 2D) of LIF. We then asked whether the expression of the
known pluripotency markers Nanog and Oct4 (also called Pou5F1)
were affected by ChABC treatment (Figure 2E). Quantitative real
time PCR (qPCR) demonstrated that in the presence of LIF, ES
cells expressed high levels of Nanog and Oct4; these levels of
expression were not altered by treatment with ChABC. This result
is consistent with the lack of CS molecules in undifferentiated ES
cells shown in Figure 1. Withdrawal of LIF lead to a reduction of
both Nanog and Oct4 expression (Figure 2E), as previously
described. In this context, ChABC treatment did not affect Oct4
mRNA levels, but caused an additional significant reduction in
Nanog mRNA levels (Figure 2E). We also used Western blot
analysis (Figure 2F) to quantify Nanog and Oct4 protein levels
(Figure 2G). Similar to our mRNA analysis, ChABC did not affect
protein levels in ES cell cultures in the presence of LIF
(Figure 2F,G). Withdrawal of LIF caused a reduction of Nanog
and Oct4 protein levels, and concomitant treatment with ChABC
Figure 5. Elimination of CS leads to increased Wnt/beta-catenin signaling, and has a biphasic effect on cardiac foci formation. (A)
Western blot analysis of TGFbeta, BMP, MAPK and Wnt/beta-catenin signaling pathways in control and ChABC-treated day 9 EB cultures
(representative blots shown). No significant differences were detected in the levels of BMP signaling (levels of phosphorylated Smad1 (pSmad1) were
corrected for total Smad1/5 levels), TGFbeta signaling (pSmad2 corrected for total Smad2 levels), Erk signaling (pErk corrected for total Erk levels), and
p38 signaling (p-p38 corrected for total p38 levels). A significant induction of beta-catenin levels was observed with ChABC treatment (beta-catenin
was corrected for total alpha-tubulin levels; p,0.05). Levels of pLRP6 were 5-fold increased in ChABC-treated EB cultures when compared to control
cultures (p,0.05). Quantitation was performed on three independent experiments. (B,C) TOPFLASH luciferase reporter assays for Wnt/beta-catenin
signaling activity. Transient transfection of the TOPFLASH reporter into ES cells cultured in the absence of LIF (B), or EB cultures (C), was followed by
treatment with conditioned media containing Wnt3a ligand (W3a-CM), or control conditioned media (L-CM). Treatment with ChABC led to a
significant increase in TOPFLASH reporter activity in both ES cells (B) and EBs (C). (D) Biphasic role of ChABC in cardiac foci formation. EB cultures were
treated with ChABC either from d0 to d4, or from d6 to d12, followed by quantification of beating cardiac foci. Early treatment from d0 to d4 led to a
significant increase in the numbers of cardiac foci, while late treatment (d6 to d12) caused a significant reduction in numbers of cardiac foci. (*: p,
0.05).
doi:10.1371/journal.pone.0092381.g005
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caused an additional significant reduction in Nanog protein levels,
while not significantly affecting Oct4 levels (Figure 2G). These
results show that endogenous CS could affect the expression of
some pluripotency markers in ES cells once differentiation has
been initiated.
CS Play a Role in Cardiac Differentiation of EB Cultures
In the next set of experiments, we asked whether treatment with
ChABC could identify a role for endogenous CS in the lineage-
specific differentiation of EBs (Figure 3). For this, ES cells were
differentiated in EB cultures, and treated bi-daily with ChABC, as
indicated in Figure 1A. Treatment with ChABC efficiently
digested CS chains in these cultures (Figure 1C). Elimination of
CS did not affect the overall appearance of EB cultures on either
day 4 or day 12 of differentiation (Figure 3A). We then prepared
mRNA from EB cultures on days 0, 3, 6, 9 and 12 and analyzed
expression of lineage markers by qPCR (Figure 3B). The
pluripotency markers Oct4 and Nanog severely decreased during
differentiation, as expected. Treatment with ChABC did not affect
the loss of Oct4 and Nanog in this time course experiment, apart
from a temporary reduction of Oct4 on day 3. Expression of the
early ectoderm marker fibroblast growth factor-5 (Fgf5) spiked on day
3 in control cultures, and then decreased drastically in later time
points. Treatment with ChABC showed the same pattern, with
somewhat reduced expression on day 3 when compared to
controls. Expression of the endoderm marker alpha-fetoprotein (Afp)
was initiated only after day 6, and rose steadily thereafter in
control cultures. The same pattern was present with ChABC
treatment; however, Afp expression was reduced by 20% at day 12.
Expression of the early and axial mesoderm marker Brachyury
spiked on day 6, and was indistinguishable between control and
ChABC-treated cultures. Mesogenin as a marker of paraxial
mesoderm also spikes on day 6, but expression did not decline
as fast as expression of Brachyury. Treatment with ChABC lead to
an increased expression of Mesogenin on day 9, but was
equivalent to controls on day 12. We next investigated markers
of cardiac differentiation in our experimental setup. The
transcription factors Gata4 and Nkx2.5 are early determinants of
cardiac differentiation. Expression of these two factors started
between days 3 and 6 and peaked on day 9, followed by a
reduction on day 12 in control conditions. Interestingly, treatment
with ChABC led to an approximately 50% reduction in Gata4 and
Nkx2.5 expression on day 12 (Figure 3B). To corroborate these
findings, we analyzed expression of myosin light chain -2 ventricle (Mlc-
2v), a marker of differentiated cardiomyocytes. Expression started
only after day 6, which is consistent with the onset of
cardiomyocyte differentiation in these EB cultures, and increased
dramatically on day 12 in control cultures. EB cultures treated
with ChABC displayed a severe reduction of Mlc-2v expression on
day 12 when compared to controls (Figure 3B). In order to
independently verify this effect on cardiac lineage markers, we
analyzed and quantified expression of cardiac myosin heavy chain
protein (MHC) by Western blot analysis (Figure 3C,D). Indeed,
MHC protein levels were significantly reduced by treatment of
Figure 6. Treatment with exogenous CS-E represses Wnt/beta-catenin signaling in ES cells and EB cultures. (A) Immunofluorescence
detection of beta-catenin (green) in ES cells in the absence of LIF (nuclei are stained blue with DAPI). Cells cultured in the absence of LIF and treated
with the control L-CM did not show any nuclear beta-catenin, but low levels of membrane-bound beta-catenin; treatment with either C4S or CS-E did
not alter levels or distribution of beta-catenin. When cultures were stimulated with W3a-CM, we observed a strong increase in nuclear accumulation
of beta-catenin (red arrows). This nuclear accumulation was not altered by treatment with C4S, but was completely abolished by treatment with CS-E.
Scale bar = 5 micrometer. (B,C) TOPFLASH reporter assays. In both ES cells cultured in the absence of LIF (B) and EBs on d10 of differentiation (C),
treatment with exogenous CS-E could significantly inhibit TOPFLASH reporter activity induced by W3a-CM, while treatment with exogenous C4S had
no significant effect. (*: p,0.05).
doi:10.1371/journal.pone.0092381.g006
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EBs with ChABC (Figure 3C,D). Together, these results showed
that elimination of endogenous CS molecules affected the
development of the cardiac lineage, while the development of
other lineages appeared not significantly disturbed.
Elimination of Endogenous CS Inhibits the Formation of
Beating Cardiac Foci
EB cultures have been shown to initiate and maintain the
formation of functional cardiomyocytes into beating cardiac foci,
which can be observed and quantified microscopically [51,52].
Since ChABC treatment reduced expression of cardiomyocyte
markers, we wanted to determine whether the development of
functional beating cardiac foci was also affected. For this, we
quantified the number of beating cardiac foci in relation to the
number of EBs plated, in both control and EB cultures treated bi-
daily with ChABC, in eight independent experiments (Figure 4A).
Our data showed that bi-daily treatment with ChABC from day 0
to day 12 caused a consistent and significant reduction in the
number of beating cardiac foci, with an average reduction of
approximately 60% (Figure 4A). We then determined the
temporal role of CS in cardiac foci formation in time course
experiments (Figure 4B). In four independent experiments, we
showed that the earliest time point beating foci were detectable
was on day 8 of EB differentiation; in untreated cultures, the
number of beating foci subsequently increased drastically, with a
peak on day 11 to 12 (Figure 4B). Numbers of cardiac foci
plateaued day 12 until day 15, and subsequently declined again
(data not shown). Importantly, treatment with ChABC signifi-
cantly decreased cardiac foci formation from the earliest time
points on, when compared to control cultures (Figure 4B).
Together with our data presented in Figure 3, these results
indicated that the absence of endogenous CS interferes with the
Figure 7. CS-E expression in EB cultures and proliferation. (A) The CS-E-specific antibody GD3G7 detected widespread expression of CS-E
moieties (no treatment). In the absence of primary antibody (no primary Ab), or after treatment with ChABC (ChABC treatment), no specific signal was
observed. (Scale bar = 100 micrometer). (B) Quantification of proliferation by EdU incorporation in EB cultures, in the presence and absence of
treatments with ChABC, C4S and CS-E. At either d6 or d12 of EB cultures, elimination of endogenous CS by treatment with ChABC, or treatment with
exogenous C4S or CS-E did not significantly alter the percentage of EdU-positive cells when compared to untreated controls.
doi:10.1371/journal.pone.0092381.g007
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initial formation of beating cardiac foci through impaired cardiac
differentiation.
ChABC Treatment Activates the Wnt/Beta-catenin
Pathway
In order to obtain a better mechanistic understanding of the
observed roles of endogenous CS in cardiac differentiation, we
analyzed the activities of several candidate signaling pathways
known to affect cardiac development [53] (Figure 5). For this, we
analyzed and quantified protein lysates of control and ChABC-
treated EB cultures by western blot for activities of the TGFbeta,
BMP, MAPK and Wnt/beta-catenin pathways (Figure 5A). No
significant differences were detected in the levels of BMP signaling
(levels of phosphorylated Smad1 (pSmad1) were corrected for total
Smad1/5 levels), TGFbeta signaling (pSmad2 corrected for total
Smad2/3 levels), Erk signaling (pErk corrected for total Erk levels),
and p38 signaling (p-p38 corrected for total p38 levels). However,
we observed a significant induction of beta-catenin levels with
ChABC treatment (beta-catenin was corrected for total alpha-
tubulin levels) (Figure 5A). This effect on Wnt/beta-catenin
signaling was confirmed by western blot analysis of LRP6 receptor
phosphorylation, a critical step in Wnt/beta-catenin pathway
activation. Indeed, pLRP6 levels were 5-fold increased in ChABC-
treated EB cultures when compared to control cultures (Figure 5A).
These results indicated that endogenous CS play an important role
in negatively controlling the Wnt/beta-catenin pathway at the
receptor level, while not affecting TGFbeta, BMP, or MAPK
pathways. We next wanted to corroborate this effect of ChABC
treatment on Wnt/beta-catenin signaling by TOPFLASH lucifer-
ase reporter assays, a frequently used transcriptional readout for
Wnt/beta-catenin signaling activity. Transient transfection of the
TOPFLASH reporter into ES cells cultured in the absence of LIF,
or EB cultures, was followed by treatment with conditioned media
containing Wnt3a ligand (W3a-CM), or control conditioned media
(L-CM). Treatment with ChABC led to a significant increase in
Figure 8. Treatment with exogenous CS-E has a biphasic role in
cardiac foci development. (A) Treatment of EB cultures with
exogenous CS-E, but not C4S, from d0 to d4 significantly decreased
cardiac foci formation. Three independent experiments and average are
shown. (* = p,0.05). (B) Treatment of EB cultures with exogenous CS-E,
but not C4S, from d6 to d12 significantly increased cardiac foci
formation. Three independent experiments and average are shown.
(* = p,0.05). (C) Expression of Mlc-2v by qPCR. Treatment of EB cultures
with exogenous CS-E, but not C4S, from d0 to d4 significantly
decreased Mlc-2v expression. Treatment with exogenous CS-E, but
not C4S, from d6 to d12 significantly increased Mlc-2v expression.
(* = p,0.05).
doi:10.1371/journal.pone.0092381.g008
Figure 9. Model of the effects of CS on cardiac differentiation
and Wnt/beta-catenin signaling. Endogenous CS and exogenous
CS-E inhibit Wnt/beta-catenin signaling in EB cultures, leading to a
reduction in early cardiac progenitors, and an enhancement of later
differentiation steps into mature cardiomyocytes.
doi:10.1371/journal.pone.0092381.g009
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TOPFLASH reporter activity in both ES cells (Figure 5B) and EBs
(Figure 5C). Together, these results demonstrated that during EB
differentiation, endogenous CS could negatively regulate Wnt/b-
catenin signaling through impairment of Wnt receptor complex
activation. Elimination of these endogenous CS leads to increased
Wnt/beta-catenin signaling.
Biphasic Role of Endogenous CS in Cardiac
Differentiation
Wnt/beta-catenin signaling has previously been established to
play a biphasic role in cardiac differentiation of EBs [44,45,46].
Specification of early cardiac progenitor cells is promoted, while
later differentiation of progenitor cells into cardiomyocytes is
repressed by Wnt/beta-catenin signaling [44,45,46]. Since we
showed above that endogenous CS could negatively regulate the
Wnt/beta-catenin pathway in EBs, we hypothesized that CS has a
similar biphasic role in cardiac differentiation through its ability to
regulate the Wnt/beta-catenin pathway. If this hypothesis is
correct, we would expect that ChABC treatment only at early
stages of EB differentiation might increase cardiac differentiation
and cardiac foci formation, since it would activate a positive
regulator of early cardiac progenitor development. Conversely,
ChABC treatment only at later stages would be expected to
decrease cardiac differentiation, since it would activate a now
negative regulator of cardiomyocyte differentiation. For these
experiments, EB cultures were treated with ChABC either from
day 0 to day 4, or from day 6 to day 12, followed by quantification
of cardiac foci formation (Figure 5D). Early treatment from day 0
to day 4 did indeed lead to a significant increase in cardiac foci
formation, while late treatment from day 6 to day 12 caused a
significant reduction in cardiac foci (Figure 5D). These results
suggest that endogenous CS could mimic the known biphasic roles
of Wnt/beta-catenin signaling during EB cardiac differentiation.
Exogenous CS-E Can Negatively Regulate Wnt/Beta-
catenin Signaling in EB Cultures
In this next set of experiments, we wanted to determine whether
specific sulfation forms of chondroitin mediate the observed
repressive effect on Wnt/beta-catenin signaling. We and others
have recently shown that CS-E, but not other CS forms, can
function as a potent inhibitor of the Wnt/beta-catenin pathway in
fibroblasts [8,47] and breast cancer cells (Willis and Klu¨ppel,
unpublished results). Thus, we initiated immunofluorescence
studies to test whether treatment with exogenous CS-E at 100
microgramm/ml, previously shown to elicit a maximum inhibition
of Wnt/beta-catenin signaling in NIH3T3 fibroblasts [8], could
interfere with Wnt/beta-catenin nuclear accumulation in response
to Wnt3a stimulation in differentiating ES cells (Figure 6A). As a
control, ES cells were treated with exogenous C4S, a chondroitin
sulfation form that has been shown not to affect Wnt/beta-catenin
signaling [8,47]. Control ES cells cultured in the absence of LIF
and treated with the control L-CM did not show any nuclear beta-
catenin, but low levels of membrane-bound beta-catenin; treat-
ment with either C4S or CS-E did not alter the levels or
distribution of beta-catenin. When cultures were stimulated with
W3a-CM, we observed a strong increase in nuclear accumulation
of beta-catenin. This nuclear accumulation was not altered by
treatment with C4S, but was completely abolished by treatment
with CS-E (Figure 6A). These results demonstrated that CS-E, but
not C4S, could function as a potent inhibitor of beta-catenin
activation in differentiating ES cells. We extended these findings
by analyzing TOPFLASH reporter activities in either ES cells
cultured in the absence of LIF (Figure 6B), or EBs at d10 of
differentiation (Figure 6C). In both cases, treatment with
exogenous CS-E could significantly inhibit TOPFLASH reporter
activity induced by W3a-CM, while treatment with exogenous
C4S had no significant effect (Figures 5B,C). Together, these
results demonstrated that exogenous CS-E, but not C4S, could
inhibit Wnt/beta-catenin signaling in differentiating ES cells and
EB cultures.
CS-E Expression in EB Cultures
Next, we wanted to determine whether endogenous CS-E is
present in EB cultures. For this, cultures were fixed at d12 and
subsequently incubated with the previously developed antibody
GD3G7 specific for CS-E epitopes [54,55,56] (Figure 7A).
GD3G7 detected widespread expression of CS-E moieties
(Figure 7A, no treatment); in the absence of primary antibody
(Figure 7A, no primary Ab), or after treatment with ChABC
(Figure 7A, ChABC treatment), no specific signal was observed.
These data demonstrated that CS-E-containing proteoglycans are
expressed in our EB cultures.
Chondroitin Sulfates do not Affect Proliferation of EB
Cultures
We have shown above that chondroitin sulfates can control
Wnt/beta-catenin signaling, a pathway that controls cell fate
decisions as well as proliferative responses [35]. In order to
determine whether our treatments affect proliferation of EBs, we
analyzed and quantified incorporation of the nucleotide analog
EdU in EB cultures, in the presence and absence of treatments
with ChABC, C4S and CS-E. At either d6 or d12 of EB cultures,
elimination of endogenous CS by treatment with ChABC, or
treatment with exogenous C4S or CS-E did not significantly alter
the percentage of EdU-positive cells when compared to untreated
controls (Figure 7B). These results suggest that endogenous and
exogenous chondroitin sulfates do not affect cell proliferation in
our EB cultures.
Biphasic Effect of Treatment with Exogenous CS-E on
Cardiac Differentiation
We next set out to investigate whether treatment with
exogenous CS-E could be used to drive cardiac differentiation of
EB cultures, and whether CS-E treatment would display the same
biphasic effects we observed with the elimination of endogenous
CS. For this, EB cultures were treated with exogenous CS-E from
either day 0 to day 4 (Figure 8A), or at later stages from day 6 to
day 12 (Figure 8B). As a control, cultures were treated with C4S,
which does not affect Wnt/beta-catenin signaling (Figure 6, and
[8,47]). We again hypothesized that treatment with CS-E at early
stages of EB differentiation would decrease cardiac differentiation
and cardiac foci formation, since CS-E could function as an
inhibitor of Wnt/beta-catenin signaling. Conversely, CS-E treat-
ment only at later stages would be expected to increase cardiac
differentiation, since it would inhibit a pathway that now
negatively regulates cardiomyocyte differentiation. Indeed, treat-
ment of EB cultures with CS-E from day 0 to day 4 decreased
cardiac foci formation (Figure 8A) and Mlc-2v expression
(Figure 8C), while treatment with exogenous CS-E from day 6
to day 12 strongly increased cardiac foci formation (Figure 8B) and
Mlc-2v expression (Figure 8C). In contrast, treatment with C4S did
not affect cardiac foci formation by either early (Figure 8A) or late
(Figure 8B) treatments, nor did C4S have any effect on Mlc-2v
expression (Figure 8C). These results demonstrated that treatment
with exogenous CS-E exhibited a biphasic role in cardiac
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differentiation, and that treatment at later stages of EB differen-
tiation could be utilized to enhance cardiac differentiation.
Discussion
In this study, we describe a novel role of CS as biphasic
regulators of cardiac differentiation of ES cells. Specifically, we
show that elimination of endogenous CS at early stages promotes
cardiac differentiation, whereas elimination of CS at later stages
promotes cardiac differentiation. Treatment with exogenous CS-E
could mimic these biphasic effects. Mechanistically, CS functioned
through negative regulation of the Wnt/beta-catenin signaling
cascade, in itself a known biphasic regulator of cardiac stem cell
differentiation (Figure 9). This work represents the first study to
shed light on the functional roles of CS in mammalian cardiac cell
lineage determination. The phenotypic similarities between
ChABC and CS-E treatments presented here suggest that CS-E
might be the main endogenous CS in the control of cardiac
differentiation through Wnt/beta-catenin signaling. This is sup-
ported by several lines of evidence: we show here that treatment
with C4S did not show any of the effects we observed with CS-E
treatments. Moreover, we demonstrate here and in previous work
that CS-E, but not other forms of CS, could interfere with Wnt/
beta-catenin signaling. However, we cannot exclude the possibility
that chondroitin sulfate forms other than CS-E or C4S might
contribute to cardiac differentiation by mechanisms independent
from the control of Wnt/beta-catenin signaling. We also
demonstrated that CS-E has a strong inhibitory effect on Wnt/
beta-catenin signaling, a known regulator of cardiac differentia-
tion. These results, however, do not exclude the possibility that
CS-E also affects cardiac differentiation through mechanisms
independent of its role as of Wnt/beta-catenin inhibitor. Future
studies into the global roles of CS-E in cellular signaling events
during cardiac differentiation will expand our knowledge in
regards to the mechanistic actions of CS-E.
Several studies have highlighted cardiac expression domains of
CS and enzymes involved in CS biosynthesis. For example, we
showed previously that C4st-1 is expressed in mouse embryonic
heart from embryonic day 9 on, with initial expression in the
atrioventricular canal, and strong expression in cardiac valves, the
atrial myocardium and the outflow tract at later stages of
embryogenesis [4]. A study in zebrafish has analyzed the roles of
CS in heart development [57]. The authors showed that
enzymatic and genetic ablation of CS in the developing heart
caused defects in atrioventricular canal formation. Whether these
results from zebrafish can be translated into the mammalian
system is unknown. Interestingly, missense mutations in the
human Carbohydrate sulfotransferase 3 (CHST3) gene have been
shown to be associated with Omani-type spondyloepiphyseal
dysplasia. A subset of these patients exhibit mild cardiac
abnormalities, including mitral, tricuspid and aortic regurgitations
[26]. In contrast, CHST3 knock-out mice and have neither skeletal
nor cardiac defects [27]. Thus, the precise role of CHST3 in
cardiac development and disease is not clear. A better mechanistic
understanding of the roles of CS and its biosynthesis machinery in
heart development is critical in order to better understand its role
in cardiac disease and evaluate its potential as a pharmacological
target.
While the roles of CS in mammalian heart development are not
well understood, increasing evidence supports the notion that CS-
containing proteoglycans (CSPGs) plays critical roles during
cardiovascular injury. The CS side chains of the CSPG Biglycan
can control elastin assembly in vascular walls [58], and targeted
disruption of biglycan leads to abnormal collagen fibrils and aortic
dissection and rupture [59]. Biglycan is also required for adaptive
remodeling after myocardial infarction [60]. A recent study
showed that CS molecules in myocardial scar tissue after
ischemia-reperfusion-induced cardiac infarction could inhibit
sympathetic nerve re-innervation into the injured area [61]. This
was due to CS side chains on the CSPG protein tyrosine
phosphatase sigma (PTPRS) in the injured region. This inhibitory
role of CS on nerve regeneration appears similar to its roles in the
glial scar in spinal cord injury. However, a role for CS in the
regeneration of cardiomyocytes has not been established by this
study. It will be interesting to determine whether the principle of a
biphasic role of CS in cardiomyocyte differentiation identified here
could be developed into a regenerative strategy in which a
temporal modulation of CS levels and/or its sulfation balance, or
treatment with exogenous CS-E, could promote stem cell
differentiation into functional cardiomyocytes in vitro and/or in vivo
after heart injury.
From a signaling point of view, this work has important
pharmacological implications. Aberrantly activated Wnt/beta-
catenin signaling has been associated in a number of human
diseases and malignancies, including cancer, fibrosis, and cardio-
vascular disease [32,33,35,36,62,63]. Thus, much effort has gone
into the identification and characterization of Wnt pathway
inhibitors, although translation of this research into clinical
applications has not been successful thus far [64,65,66,67]. Our
previous results, together with the results presented here, suggest
that the CS biosynthesis machinery could be an important
pharmacological target to control aberrant Wnt/beta-catenin
signaling in a number of biological and pathological systems,
including cardiovascular disease.
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